Mainz Biomed BV (MYNZ)

[crudeoil24]

IPO today > Mainz Biomed (ticker: MYNZ) was the first of the group to begin trading, also on the Nasdaq. Shares kicked off at $14.35, hit a high of $17.48 and recently changed hands at $12.64, up 153% from its offer price.

Mainz Biomed was formed earlier this year to acquire PharmGenomics, a German biotech that makes in vitro diagnostic tests for the early detection of cancer, a prospectus said. Its flagship product, ColoAlert, is used to catch colorectal cancer. Another product in the early stages of research is PancAlert, which tests for pancreatic cancer. Mainz raised $10 million after selling 2 million shares at $5 each, the middle of its $4 to $6 price range.